Stuart Crow – Non Executive Chairman – Lake Resources N.L. (ASX:LKE, OTC: LLKKF) is a responsible lithium developer utilising state of-the-art ion exchange extraction technology for production of sustainable, high purity lithium from its flagship Kachi Project in Catamarca Province within the Lithium Triangle in Argentina. Lake also has three additional early-stage projects in this region.
Copyright 2024 – Finance News Network
30 Mar 2022 - BluGlass Limited (ASX:BLG) Executive Chair discusses the acquisition of a semiconductor manufacturing lab in Fremont in the Silicon Valley.
27 Nov 2020 - Novatti Group Limited (ASX:NOV) Managing Director & CEO Peter Cook talks about the company's recently announced partnerships with UnionPay, Google Pay and Samsung Pay.
31 Mar 2021 - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q) CEO and Managing Director James Graham talks about progress with the company's lead anti-infective candidate Recce 327, its expanding portfolio of synthetic anti-infectives targeting viral pathogens and a broad range of bacteria, clinical trial results and priorities for 2021.
12 Aug 2021 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun provides an introduction to the company's platform, partners and retail brands, discussing how it grows sales in China through a combination of data and technology.
30 Jul 2024 - Brendan Bradley - Managing Director - DevEx Resources (ASX:DEV) is an exploration company with a diversified portfolio of high-quality projects spanning some of Australia’s best endowed mining regions.
14 Nov 2023 - Explore Chariot Corporation (ASX:CC9) US lithium projects with CEO Shanthar Pathmanathan and geological consultant Dr. Edward Max Baker. Discover the progress at the flagship Black Mountain drill and key milestones ahead.
15 Jul 2020 - Recce Pharmaceuticals Limited (ASX:RCE) Executive Director James Graham provides an update on positive data against a range of persistent bacteria using the company's synthetic antibiotic RECCE 327, commencement of Phase I human clinical trial in 2H20 and key priorities.
